Li Shaoying, He Jianchun, He Wenzhi, Xian Jiajia, Huang Lingling, Zhao Gengye, Zhang Xin, Du Renqian, Chu Liming, Wang Yueqiang, Kong Lingyin, Liang Bo, Li Qing
Department of Obstetrics and Gynecology, Experimental Department of Obstetrics and Gynecology Institute, Guangdong Provincial Key Laboratory for Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, Guangdong-Hong Kong-Macao Greater Bay Area Higher Education Joint Laboratory for Maternal-Fetal Medicine, the Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510150, China.
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2024 Mar 10;41(3):294-299. doi: 10.3760/cma.j.cn511374-20221109-00777.
To explore the clinical application of preimplantation genetic testing for monogenic disorders (PGT-M) in an unique case with Spinal muscular atrophy (SMA) type 2+0.
A special SMA family presented at the Third Affiliated Hospital of Guangzhou Medical University on October 19, 2020 was selected as the study subject. Multiple ligation-dependent probe amplification (MLPA) and molecular tagging linkage analysis were carried out to identify the SMN1 genotype of the couple and their fetus. Subsequently, next-generation sequencing (NGS), molecular tagging linkage analysis, and chromosomal microarray analysis were employed to determine the haplotypes and validate the result of PGT-M on the 11 embryos derived for the couple.
The female partner was identified as a carrier of the rare SMN1[2+0] variant, and prenatal diagnosis confirmed the fetus to be affected by SMA. Ultimately, PGT-M has successfully selected four embryos free from the pathogenic SMN1 variants and X chromosome deletion.
PGT-M can effectively prevent the transmission of rare genetic variants such as the SMA 2+0 subtype in the families. Above finding has provided guidance for genetic counseling and family planning for the couple.
探讨单基因病胚胎植入前基因检测(PGT-M)在1例特殊的2型脊髓性肌萎缩症(SMA)合并0型的病例中的临床应用。
选取2020年10月19日就诊于广州医科大学附属第三医院的一个特殊SMA家系作为研究对象。采用多重连接依赖探针扩增技术(MLPA)和分子标签连锁分析确定这对夫妇及其胎儿的SMN1基因分型。随后,运用二代测序(NGS)、分子标签连锁分析和染色体微阵列分析确定单倍型,并验证对该夫妇获取的11个胚胎进行PGT-M的结果。
女性伴侣被鉴定为罕见的SMN1[2+0]变异携带者,产前诊断证实胎儿患有SMA。最终,PGT-M成功筛选出4个未携带致病性SMN1变异和X染色体缺失的胚胎。
PGT-M可有效防止SMA 2+0亚型等罕见遗传变异在家族中的传递。上述发现为该夫妇的遗传咨询和计划生育提供了指导。